Funded Startups in Exton
Exton’s most recent disclosed rounds are concentrated in life sciences, with Biotechnology appearing in 3 of the 6 entries (Praeventix on 2026-02-13 for $3…
Exton’s most recent disclosed rounds are concentrated in life sciences, with Biotechnology appearing in 3 of the 6 entries (Praeventix on 2026-02-13 for $3M; Castle Creek Biosciences on 2022-05-02 for $113M; Immunome on 2021-07-20 for $18M). The disclosed-size distribution is sharply skewed: Castle Creek Biosciences’ $113M round on 2022-05-02 dwarfs the next-highest disclosed amount of $18M (Immunome, 2021-07-20), while one other disclosed biotech round is far lower at $3M (Praeventix, 2026-02-13).
Timing shows an older anchor with a 2021–2022 cluster alongside newer activity: the window spans 2021-07-20 through 2026-02-13, and 3 of the 6 rows fall in 2021–2022 (Immunome 2021-07-20, Castle Creek Biosciences 2022-05-02, Agronomed Pharmaceuticals 2022-12-21). Stage/classification data is frequently non-specific: 4 of 6 entries are labeled Series Unknown or undisclosed amounts (Energage 2024-10-31 is undisclosed; 12Port Inc 2024-09-04 is undisclosed; Praeventix and other non-undisclosed rows are Series Unknown).
Most recent rounds
6 shownRelated listings
Frequently asked
Which disclosed round is the outlier in Exton, and how much larger is it than the rest?
Castle Creek Biosciences’ $113M round on 2022-05-02 is the only disclosed amount above $100M. The next-highest disclosed amount is $18M for Immunome on 2021-07-20, so the outlier dwarfs the rest of the disclosed figures in this set.
Are there sector clusters in Exton across these most recent entries?
Biotechnology is over-represented relative to other categories, appearing in 3 of 6 entries: Praeventix (2026-02-13, $3M), Castle Creek Biosciences (2022-05-02, $113M), and Immunome (2021-07-20, $18M). The remaining 3 entries split across Internet Services, Information Technology, and Community and Lifestyle.
Do the round dates cluster toward a specific period in the last five years?
Yes. Half of the entries (3 of 6) land in 2021–2022: Immunome on 2021-07-20, Castle Creek Biosciences on 2022-05-02, and Agronomed Pharmaceuticals on 2022-12-21. The newest two entries also sit in 2024–2026 (12Port Inc on 2024-09-04 and Praeventix on 2026-02-13).
Which classification signals dominate: Series Unknown vs. undisclosed amounts?
Non-specific outcomes dominate: 4 of 6 rows are either 'Series Unknown' or have an 'undisclosed' amount (Energage on 2024-10-31 is undisclosed; 12Port Inc on 2024-09-04 is undisclosed; Praeventix and Agronomed Pharmaceuticals are labeled Series Unknown even though their amounts are disclosed). Only Immunome shows a named stage category ('Grant') alongside a disclosed $18M.
What stage mix stands out among the disclosed rounds in this Exton snapshot?
Among disclosed amounts, the largest disclosed entry (Castle Creek Biosciences on 2022-05-02 for $113M) is categorized as 'Venture - Series Unknown,' while Immunome (2021-07-20 for $18M) is a 'Grant' and Praeventix (2026-02-13 for $3M) is 'Series Unknown.' The disclosed figures therefore span a venture-labeled unknown series, a grant, and a generic series-unknown classification.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.